Quick recap of what today's news means..... Bre
Post# of 1418
(Total Views: 366)
Posted On: 05/28/2019 8:13:33 PM
Quick recap of what today's news means.....
Breakthrough Diagnostics
In December 2018, Amarantus announced a Joint Venture agreement with Todos Medical (OTC:TOMDF) to develop the Alzheimer's blood diagnostic 'LymPro Test 2.0'. The Joint Venture is called Breakthrough Diagnostics, Inc. ("Breakthrough"
. Under the terms of the agreement, Amarantus will receive 19.99% of equity in Todos, and Todos will receive 19.99% of the equity in Breakthrough, with Todos also providing initially $500,000 to fund certain license and development costs, as well as the retention of key management to drive the program forward. Todos has an option to acquire the remaining 80.01% of Breakthrough upon the achievement of certain milestones, in exchange for a total of 50% of Todos shares (inclusive of shares issued to Amarantus via the Joint Venture). Todos owns rights to potentially revolutionary technology in the early detection of cancer based on proprietary blood immune markers, with tests for breast cancer and colorectal cancer having already received regulatory authorization in Europe. We expect the Joint Venture transaction to be completed in the first quarter of 2019.
https://www.amarantus.com/news/press-releases...19-roadmap
Aloha
Breakthrough Diagnostics
In December 2018, Amarantus announced a Joint Venture agreement with Todos Medical (OTC:TOMDF) to develop the Alzheimer's blood diagnostic 'LymPro Test 2.0'. The Joint Venture is called Breakthrough Diagnostics, Inc. ("Breakthrough"
. Under the terms of the agreement, Amarantus will receive 19.99% of equity in Todos, and Todos will receive 19.99% of the equity in Breakthrough, with Todos also providing initially $500,000 to fund certain license and development costs, as well as the retention of key management to drive the program forward. Todos has an option to acquire the remaining 80.01% of Breakthrough upon the achievement of certain milestones, in exchange for a total of 50% of Todos shares (inclusive of shares issued to Amarantus via the Joint Venture). Todos owns rights to potentially revolutionary technology in the early detection of cancer based on proprietary blood immune markers, with tests for breast cancer and colorectal cancer having already received regulatory authorization in Europe. We expect the Joint Venture transaction to be completed in the first quarter of 2019. https://www.amarantus.com/news/press-releases...19-roadmap
Aloha
(1)
(0)